MediciNova Provides Development Update on MN-221 and MN-166

MediciNova Provides Development Update on MN-221 and MN-166

By: Latest Articles from Benzinga.com

Posted on January 03, 2013 at 19:18 PM EST

MediciNova (NASDAQ: MNOV ) provides a development update on its two lead programs, MN-221 and MN-166. End-of-phase 2 guidance from the FDA and the newly extended patent protection (to expire no earlier than 2030) for use of MN-221 in the treatment of acute exacerbations of asthma (AEA) provide a clear

Related Stocks:

Medicinova, Inc. NewStar Financial, Inc.

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates